- Report
- February 2024
- 70 Pages
New Zealand
From €4279EUR$4,750USD£3,775GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4279EUR$4,750USD£3,775GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4279EUR$4,750USD£3,775GBP
- Report
- February 2024
- 80 Pages
Europe
From €4279EUR$4,750USD£3,775GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4279EUR$4,750USD£3,775GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4279EUR$4,750USD£3,775GBP
- Report
- August 2023
- 110 Pages
Global
From €4279EUR$4,750USD£3,775GBP
- Report
- August 2023
- 80 Pages
Africa, Middle East
From €4279EUR$4,750USD£3,775GBP
- Report
- October 2022
- 70 Pages
Africa
From €4279EUR$4,750USD£3,775GBP
- Report
- May 2024
- 128 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- May 2024
- 140 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- May 2024
- 140 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- May 2024
- 139 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- May 2024
- 130 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- May 2024
- 134 Pages
Global
From €4976EUR$5,524USD£4,391GBP
€5854EUR$6,499USD£5,165GBP
- Report
- June 2024
- 183 Pages
Global
From €4054EUR$4,500USD£3,577GBP
- Report
- August 2024
- 178 Pages
Global
From €2252EUR$2,500USD£1,987GBP
- Report
- January 2024
- 150 Pages
Global
From €3468EUR$3,850USD£3,060GBP
€4369EUR$4,850USD£3,855GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3108EUR$3,450USD£2,742GBP
- Report
- October 2022
- 177 Pages
From €3108EUR$3,450USD£2,742GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more